Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Oppenheimer emerging biotech analyst to hold analyst/industry conference call » 16:40
03/22/23
03/22
16:40
03/22/23
16:40
RLAY

Relay Therapeutics

$15.21 /

-0.3401 (-2.19%)

, ARVN

Arvinas

$27.65 /

-1.485 (-5.10%)

, OLMA

Olema Oncology

$3.43 /

-0.235 (-6.41%)

, AMAM

Ambrx Biopharma

$9.09 /

-0.96 (-9.55%)

, GILD

Gilead

$77.77 /

-1.38 (-1.74%)

, AZN

AstraZeneca

$66.55 /

-0.425 (-0.63%)

, LLY

Eli Lilly

$331.02 /

+0.015 (+0.00%)

Biotechnology Analyst…

Biotechnology Analyst Biegler, along with Dr. Christos Vaklavas discuss the HR+ metastatic breast cancer landscape, expectations for upcoming initial data for RLY-2608 (PI3Kalpha), unmet need for oral SERD(s), and the impact of Enhertu on the HR+ space (relevant companies RLAY, ARVN, OLMA, AMAM, GILD, AZN, LLY) on an Analyst/Industry conference call to be held on March 27 at 2 pm.

ShowHide Related Items >><<
OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

AMAM Ambrx Biopharma
$9.09 /

-0.96 (-9.55%)

RLAY Relay Therapeutics
$15.21 /

-0.3401 (-2.19%)

03/09/23 Guggenheim
Relay Therapeutics price target lowered to $28 from $45 at Guggenheim
03/07/23 H.C. Wainwright
Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright
02/02/23 Oppenheimer
Relay Therapeutics initiated with an Outperform at Oppenheimer
01/19/23 JMP Securities
Relay Therapeutics price target lowered to $28 from $38 at JMP Securities
ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

03/18/23 Citi
Arvinas price target raised to $77 from $72 at Citi
02/23/23 Capital One
Arvinas remains one of the best biotechs to own, says Capital One
01/17/23 Truist
Arvinas price target lowered to $65 from $100 at Truist
01/12/23 Capital One
Arvinas pullback a buying opportunity, says Capital One
OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

03/10/23 H.C. Wainwright
Olema Oncology price target raised to $15 from $12 at H.C. Wainwright
02/22/23 Credit Suisse
Olema Oncology initiated with an Outperform at Credit Suisse
07/06/22 Canaccord
Olema Oncology assumed with a Buy at Canaccord
06/09/22 H.C. Wainwright
H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data
AMAM Ambrx Biopharma
$9.09 /

-0.96 (-9.55%)

03/03/23 Baird
Ambrx Biopharma price target raised to $11 from $4 at Baird
10/19/22 Baird
Ambrx Biopharma price target lowered to $4 from $8 at Baird
09/21/22 Baird
Ambrx Biopharma price target lowered to $8 from $16 at Baird
04/07/22 Baird
Baird starts Ambrx Biopharma with Outperform, $16 price target
GILD Gilead
$77.77 /

-1.38 (-1.74%)

03/20/23 Oppenheimer
Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news
03/13/23 Stifel
Arcellx initiated with a Buy at Stifel
02/14/23 Mizuho
Gilead price target raised to $101 from $88 at Mizuho
02/10/23 TD Cowen
Gilead price target raised to $95 from $90 at Cowen
AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

03/15/23 Berenberg
AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
03/07/23 Guggenheim
Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
03/07/23 Evercore ISI
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
02/21/23 UBS
AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

03/22/23 Stifel
Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data
03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
RLAY Relay Therapeutics
$15.21 /

-0.3401 (-2.19%)

OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

  • 13
    Sep
LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

RLAY Relay Therapeutics
$15.21 /

-0.3401 (-2.19%)

OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

AMAM Ambrx Biopharma
$9.09 /

-0.96 (-9.55%)

Recommendations
Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data » 10:28
03/22/23
03/22
10:28
03/22/23
10:28
VKTX

Viking Therapeutics

$9.56 /

+0.18 (+1.92%)

, ALT

Altimmune

$4.55 /

-0.4 (-8.08%)

, LLY

Eli Lilly

$335.15 /

+4.15 (+1.25%)

Viking Therapeutics…

Viking Therapeutics (VKTX) shares traded down ~20% following the Phase 2 interim data of pemvidutide announced by Altimmune (ALT), a competing GLP-1/glucagon program in obesity, Stifel tells investors in a research note. The firm believes this reaction is undeserved due to it being a different compound altogether. Further, Stifel argues a better benchmark for comparison is Eli Lilly's (LLY) Mounjaro. Viking's VK2735 is approaching Phase 1b SAD/MAD data before the end of Q1, which the firm believes will serve to set safety/tolerability expectations and elucidate points of differentiation. Stifel reiterated a Buy rating and a $22 price target on the stock.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

03/21/23 William Blair
William Blair says Viking bull thesis intact after Altimmune data
03/16/23 Stifel
Viking Therapeutics initiated with a Buy at Stifel
02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
ALT Altimmune
$4.55 /

-0.4 (-8.08%)

03/21/23 Goldman Sachs
Altimmune downgraded to Neutral from Buy at Goldman Sachs
03/21/23 H.C. Wainwright
Altimmune attractive after 'overdone' selloff, says H.C. Wainwright
03/21/23 H.C. Wainwright
Altimmune selloff on weight loss data overdone, says H.C. Wainwright
LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

Hot Stocks
Roche to collaborate with Lilly on early diagnosis of Alzheimer's disease » 08:14
03/22/23
03/22
08:14
03/22/23
08:14
RHHBY

Roche

$35.62 /

+0.48 (+1.37%)

, LLY

Eli Lilly

$331.15 /

-2.37 (-0.71%)

Roche (RHHBY) announced…

Roche (RHHBY) announced that it has entered into a collaboration with Eli Lilly (LLY) to support the development of Roche's Elecsys Amyloid Plasma Panel, or EAPP, which it calls "an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer's disease." Roche said: "Today, barriers to early and accurate diagnosis of Alzheimer's exist across the globe with up to 75% of people living with the symptoms of Alzheimer's, but without a diagnosis. Those who have received a diagnosis waited, on average, 2.8 years after symptom onset. To address the growing strain that Alzheimer's is putting on healthcare systems, it will be essential to make a person's journey to diagnosis faster and more accessible. This will ultimately enable access to appropriate new therapies as they become available. This collaboration is aligned to both Roche and Lilly's shared objective to support patients by improving the journey to a timely and accurate diagnosis and treatment. If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis."

ShowHide Related Items >><<
RHHBY Roche
$35.62 /

+0.48 (+1.37%)

LLY Eli Lilly
$331.15 /

-2.37 (-0.71%)

RHHBY Roche
$35.62 /

+0.48 (+1.37%)

03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
02/27/23 Societe Generale
Societe Generale upgrades Roche to Buy, says 'enough is enough'
02/27/23 Societe Generale
Roche upgraded to Buy from Hold at Societe Generale
02/15/23 JMP Securities
iBio downgraded to Market Perform at JMP on CDMO and IBIO-101 questions
LLY Eli Lilly
$331.15 /

-2.37 (-0.71%)

03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
RHHBY Roche
$35.62 /

+0.48 (+1.37%)

LLY Eli Lilly
$331.15 /

-2.37 (-0.71%)

RHHBY Roche
$35.62 /

+0.48 (+1.37%)

LLY Eli Lilly
$331.15 /

-2.37 (-0.71%)

RHHBY Roche
$35.62 /

+0.48 (+1.37%)

LLY Eli Lilly
$331.15 /

-2.37 (-0.71%)

LLY Eli Lilly
$331.15 /

-2.37 (-0.71%)

Over a week ago
Recommendations
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class' » 08:50
03/17/23
03/17
08:50
03/17/23
08:50
BIIB

Biogen

$265.33 /

+3.06 (+1.17%)

, ESALY

Eisai

$61.51 /

+ (+0.00%)

, LLY

Eli Lilly

$329.54 /

+0.02 (+0.01%)

Stifel analyst Paul…

Stifel analyst Paul Matteis lowered the firm's price target on Biogen (BIIB) to $324 from $331 and keeps a Buy rating on the shares, telling investors that based on the firm's research ahead of Eli Lilly's (LLY) donanemab TRAILBLAZER-ALZ 2 readout that it is "more confident" that Biogen (BIIB) and Eisai's (ESALY) lecanemab is "best-in-class among late-stage abeta antibodies." The firm now assumes a slower initial ramp to reflect near-term CMS uncertainty, but believes this will "become a blockbuster class" and notes that its Alzheimer's disease market model is now split 60/40 for lecanemab/donanemab.

ShowHide Related Items >><<
LLY Eli Lilly
$329.54 /

+0.02 (+0.01%)

ESALY Eisai
$61.51 /

+ (+0.00%)

BIIB Biogen
$265.33 /

+3.06 (+1.17%)

BIIB Biogen
$265.33 /

+3.06 (+1.17%)

03/13/23 RBC Capital
Biogen price target raised to $350 from $335 at RBC Capital
03/09/23 BofA
No ad com suggests positive potential outcome for Sage's zura, says BofA
02/16/23 RBC Capital
Biogen price target lowered to $333 from $359 at RBC Capital
02/16/23 TD Cowen
Biogen price target raised to $315 from $300 at Cowen
ESALY Eisai
$61.51 /

+ (+0.00%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
LLY Eli Lilly
$329.54 /

+0.02 (+0.01%)

03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
03/06/23 Jefferies
Jefferies starts 'priced to perfection' Eli Lilly with a Hold
LLY Eli Lilly
$329.54 /

+0.02 (+0.01%)

BIIB Biogen
$265.33 /

+3.06 (+1.17%)

LLY Eli Lilly
$329.54 /

+0.02 (+0.01%)

ESALY Eisai
$61.51 /

+ (+0.00%)

BIIB Biogen
$265.33 /

+3.06 (+1.17%)

LLY Eli Lilly
$329.54 /

+0.02 (+0.01%)

ESALY Eisai
$61.51 /

+ (+0.00%)

BIIB Biogen
$265.33 /

+3.06 (+1.17%)

LLY Eli Lilly
$329.54 /

+0.02 (+0.01%)

BIIB Biogen
$265.33 /

+3.06 (+1.17%)

Conference/Events
Needham healthcare analyst to hold an analyst/industry conference call » 11:55
03/15/23
03/15
11:55
03/15/23
11:55
BIIB

Biogen

$259.69 /

-2.52 (-0.96%)

, LLY

Eli Lilly

$326.12 /

-0.93 (-0.28%)

Healthcare/Neuroscience…

Healthcare/Neuroscience Analysts, along with Dr. Anton Porsteinsson, in conjunction with Needham's Virtual Neuroscience Forum and provide a commercial update of BIIB's Leqembi, discuss the upcoming TRAILBLAZER-ALZ 2 data readout for LLY's donanemab on an Analyst/Industry conference call to be held on March 15 at 12:15 pm.

ShowHide Related Items >><<
LLY Eli Lilly
$326.12 /

-0.93 (-0.28%)

BIIB Biogen
$259.69 /

-2.52 (-0.96%)

BIIB Biogen
$259.69 /

-2.52 (-0.96%)

03/13/23 RBC Capital
Biogen price target raised to $350 from $335 at RBC Capital
03/09/23 BofA
No ad com suggests positive potential outcome for Sage's zura, says BofA
02/16/23 RBC Capital
Biogen price target lowered to $333 from $359 at RBC Capital
02/16/23 TD Cowen
Biogen price target raised to $315 from $300 at Cowen
LLY Eli Lilly
$326.12 /

-0.93 (-0.28%)

03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
03/06/23 Jefferies
Jefferies starts 'priced to perfection' Eli Lilly with a Hold
LLY Eli Lilly
$326.12 /

-0.93 (-0.28%)

BIIB Biogen
$259.69 /

-2.52 (-0.96%)

LLY Eli Lilly
$326.12 /

-0.93 (-0.28%)

BIIB Biogen
$259.69 /

-2.52 (-0.96%)

LLY Eli Lilly
$326.12 /

-0.93 (-0.28%)

BIIB Biogen
$259.69 /

-2.52 (-0.96%)

LLY Eli Lilly
$326.12 /

-0.93 (-0.28%)

BIIB Biogen
$259.69 /

-2.52 (-0.96%)

Conference/Events
Needham healthcare analyst to hold an analyst/industry conference call » 04:55
03/15/23
03/15
04:55
03/15/23
04:55
BIIB

Biogen

$262.25 /

+3.62 (+1.40%)

, LLY

Eli Lilly

$327.06 /

+2.54 (+0.78%)

Healthcare/Neuroscience…

Healthcare/Neuroscience Analysts, along with Dr. Anton Porsteinsson, in conjunction with Needham's Virtual Neuroscience Forum and provide a commercial update of BIIB's Leqembi, discuss the upcoming TRAILBLAZER-ALZ 2 data readout for LLY's donanemab on an Analyst/Industry conference call to be held on March 15 at 12:15 pm.

ShowHide Related Items >><<
LLY Eli Lilly
$327.06 /

+2.54 (+0.78%)

BIIB Biogen
$262.25 /

+3.62 (+1.40%)

BIIB Biogen
$262.25 /

+3.62 (+1.40%)

03/13/23 RBC Capital
Biogen price target raised to $350 from $335 at RBC Capital
03/09/23 BofA
No ad com suggests positive potential outcome for Sage's zura, says BofA
02/16/23 RBC Capital
Biogen price target lowered to $333 from $359 at RBC Capital
02/16/23 TD Cowen
Biogen price target raised to $315 from $300 at Cowen
LLY Eli Lilly
$327.06 /

+2.54 (+0.78%)

03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
03/06/23 Jefferies
Jefferies starts 'priced to perfection' Eli Lilly with a Hold
LLY Eli Lilly
$327.06 /

+2.54 (+0.78%)

BIIB Biogen
$262.25 /

+3.62 (+1.40%)

LLY Eli Lilly
$327.06 /

+2.54 (+0.78%)

BIIB Biogen
$262.25 /

+3.62 (+1.40%)

LLY Eli Lilly
$327.06 /

+2.54 (+0.78%)

BIIB Biogen
$262.25 /

+3.62 (+1.40%)

LLY Eli Lilly
$327.06 /

+2.54 (+0.78%)

BIIB Biogen
$262.25 /

+3.62 (+1.40%)

Hot Stocks
Veru says terminating Phase 3 VERACITY trial of sabizabulin » 12:40
03/14/23
03/14
12:40
03/14/23
12:40
VERU

Veru

$2.09 /

+0.06 (+2.96%)

, LLY

Eli Lilly

$322.44 /

-2.08 (-0.64%)

In a regulatory filing,…

In a regulatory filing, Veru stated that on March 14, at the Oppenheimer 33rd Annual Healthcare Conference, Dr. Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of the company, presented Veru's updated strategy as part of the company's ongoing effort to refocus its drug development efforts on those drug candidates which it believes have the best opportunity to lead to long-term success and shareholder value creation and conserve cash, including a reduction in personnel and certain other measures to reduce costs. "The presentation included a description of Veru's refocused research and development strategy which includes the following: (i) plans for continued development of sabizabulin in Phase 3 COVID-19 confirmatory study in hospitalized moderate to severe COVID-19 patients at high risk for acute respiratory disease syndrome, or 'ARDS,' and planned development of sabizabulin in Phase 3 clinical study in hospitalized influenza patients at high risk for ARDS, (ii) plans for an updated ongoing Phase 3 study of enobosarm and abemaciclib combination in the second line setting for AR+ ER+ HER2- metastatic breast cancer patients, into which Veru plans to roll the current ARTEST study, if agreed by the U.S. Food and Drug Administration and the company's clinical trial partner, Eli Lilly & Company (LLY), and (iii) a planned Phase 3 study of enobosarm in bone-only non-measurable metastatic ER+ HER2- breast cancer. In addition, Dr. Steiner announced that Veru is reserving sabizabulin for clinical development only in infectious disease indications, and accordingly, terminating the Phase 3 VERACITY trial of sabizabulin in certain prostate cancer patients. Further, Phase 2 development of the Veru-100 and zuclomiphene assets will be paused. On March 2, 2023, Veru had announced that the FDA declined to grant at this time Veru's request for Emergency Use Authorization for sabizabulin to treat hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS," the filing stated.

ShowHide Related Items >><<
VERU Veru
$2.09 /

+0.06 (+2.96%)

LLY Eli Lilly
$322.44 /

-2.08 (-0.64%)

VERU Veru
$2.09 /

+0.06 (+2.96%)

02/14/23 Oppenheimer
Veru price target lowered to $14 from $20 at Oppenheimer
02/10/23 H.C. Wainwright
Veru price target lowered to $14 from $18 at H.C. Wainwright
12/07/22 H.C. Wainwright
Veru price target lowered to $18 from $21 at H.C. Wainwright
11/10/22 H.C. Wainwright
Veru price target lowered to $21 from $24 at H.C. Wainwright
LLY Eli Lilly
$322.44 /

-2.08 (-0.64%)

03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
03/06/23 Jefferies
Jefferies starts 'priced to perfection' Eli Lilly with a Hold
VERU Veru
$2.09 /

+0.06 (+2.96%)

LLY Eli Lilly
$322.44 /

-2.08 (-0.64%)

LLY Eli Lilly
$322.44 /

-2.08 (-0.64%)

VERU Veru
$2.09 /

+0.06 (+2.96%)

LLY Eli Lilly
$322.44 /

-2.08 (-0.64%)

VERU Veru
$2.09 /

+0.06 (+2.96%)

LLY Eli Lilly
$322.44 /

-2.08 (-0.64%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:14
03/13/23
03/13
10:14
03/13/23
10:14
TSLA

Tesla

$169.38 /

-4.06 (-2.34%)

, NVEI

Nuvei

$38.76 /

+1.21 (+3.22%)

, OEC

Orion Engineered

$23.87 /

-0.66 (-2.69%)

, CBT

Cabot

$73.00 /

-1.31 (-1.76%)

, GEHC

GE HealthCare

$74.57 /

-0.44 (-0.59%)

, NKLA

Nikola

$1.69 /

+0.03 (+1.81%)

, SI

Silvergate Capital

$2.40 /

-0.17 (-6.61%)

, SIVB

SVB Financial

$105.92 /

+ (+0.00%)

, UA

Under Armour

$7.50 /

-0.345 (-4.40%)

, UAA

Under Armour

$8.44 /

-0.475 (-5.33%)

, AAP

Advance Auto Parts

$126.90 /

-1.165 (-0.91%)

, LRCX

Lam Research

$473.45 /

-5.36 (-1.12%)

, MRK

Merck

$108.08 /

+0.4 (+0.37%)

, PB

Prosperity Bancshares

$59.83 /

-4.315 (-6.73%)

, PNC

PNC Financial

$127.34 /

-9.82 (-7.16%)

, AMGN

Amgen

$235.21 /

+7.33 (+3.22%)

, LLY

Eli Lilly

$327.00 /

+12.055 (+3.83%)

, JPM

JPMorgan

$132.32 /

-1.335 (-1.00%)

Want to get stock-moving…

ShowHide Related Items >><<
UA Under Armour
$7.50 /

-0.345 (-4.40%)

TSLA Tesla
$169.38 /

-4.06 (-2.34%)

SIVB SVB Financial
$105.92 /

+ (+0.00%)

SI Silvergate Capital
$2.40 /

-0.17 (-6.61%)

PNC PNC Financial
$127.34 /

-9.82 (-7.16%)

PB Prosperity Bancshares
$59.83 /

-4.315 (-6.73%)

OEC Orion Engineered
$23.87 /

-0.66 (-2.69%)

NVEI Nuvei
$38.76 /

+1.21 (+3.22%)

NKLA Nikola
$1.69 /

+0.03 (+1.81%)

MRK Merck
$108.08 /

+0.4 (+0.37%)

LRCX Lam Research
$473.45 /

-5.36 (-1.12%)

LLY Eli Lilly
$327.00 /

+12.055 (+3.83%)

JPM JPMorgan
$132.32 /

-1.335 (-1.00%)

GEHC GE HealthCare
$74.57 /

-0.44 (-0.59%)

CBT Cabot
$73.00 /

-1.31 (-1.76%)

AMGN Amgen
$235.21 /

+7.33 (+3.22%)

AAP Advance Auto Parts
$126.90 /

-1.165 (-0.91%)

TSLA Tesla
$169.38 /

-4.06 (-2.34%)

03/13/23 Wolfe Research
Tesla downgraded to Peer Perform from Outperform at Wolfe Research
03/09/23 Morgan Stanley
Morgan Stanley questions if Tesla has 'outgrown the Cybertruck'
03/08/23 Citi
Tesla comments 'very bullish' for lithium industry, says Citi
03/08/23 Berenberg
Tesla downgraded to Hold from Buy at Berenberg
NVEI Nuvei
$38.76 /

+1.21 (+3.22%)

03/13/23 JPMorgan
Nuvei reinstated with an Overweight at JPMorgan
03/09/23 CIBC
Nuvei upgraded to Outperformer at CIBC following better than expected outlook
03/09/23 CIBC
Nuvei upgraded to Outperformer from Neutral at CIBC
03/09/23 Raymond James
Nuvei price target raised to $49 from $40 at Raymond James
OEC Orion Engineered
$23.87 /

-0.66 (-2.69%)

03/13/23 Credit Suisse
Orion Engineered initiated with an Outperform at Credit Suisse
CBT Cabot
$73.00 /

-1.31 (-1.76%)

03/13/23 Credit Suisse
Cabot initiated with an Outperform at Credit Suisse
02/13/23 Loop Capital
Cabot price target raised to $113 from $98 at Loop Capital
02/13/23 JPMorgan
Cabot price target raised to $87 from $80 at JPMorgan
11/16/22 Deutsche Bank
Cabot upgraded to Buy from Hold at Deutsche Bank
GEHC GE HealthCare
$74.57 /

-0.44 (-0.59%)

03/13/23 Evercore ISI
GE HealthCare initiated with an Outperform at Evercore ISI
03/06/23 BofA
General Electric price target raised to $96 at BofA ahead of investor day
02/17/23 Mizuho
GE HealthCare initiated with a Buy at Mizuho
01/25/23 BofA
General Electric price target raised to $92 from $85 at BofA
NKLA Nikola
$1.69 /

+0.03 (+1.81%)

03/13/23 Morgan Stanley
Nikola initiated with an Equal Weight at Morgan Stanley
02/24/23 Deutsche Bank
Nikola price target lowered to $3 from $5 at Deutsche Bank
02/24/23 TD Cowen
Nikola price target lowered to $5 from $10 at Cowen
01/17/23 BTIG
Nikola price target lowered to $5 from $7 at BTIG
SI Silvergate Capital
$2.40 /

-0.17 (-6.61%)

03/13/23 DA Davidson
DA Davidson upgrades Prosperity Bancshares to Buy on 'great defensive' qualities
03/13/23 Morgan Stanley
Fed's new funding program a positive for Charles Schwab, says Morgan Stanley
03/13/23 BofA
Charles Schwab price target lowered to $60 from $74 at BofA
03/13/23 Oppenheimer
Coinbase price target lowered to $70 from $84 at Oppenheimer
SIVB SVB Financial
$105.92 /

+ (+0.00%)

03/13/23 Citi
Citi cuts Bill target but says risk/reward favorable after selloff
03/13/23 BofA
BofA removes rating on First Republic after SVB, Signature failures
UA Under Armour
$7.50 /

-0.345 (-4.40%)

03/13/23 JPMorgan
Under Armour downgraded to Neutral from Overweight at JPMorgan
02/09/23 Morgan Stanley
Under Armour price target raised to $10 from $8 at Morgan Stanley
02/09/23 Citi
Under Armour price target lowered to $12 from $13 at Citi
02/06/23 Deutsche Bank
Under Armour price target raised to $14 from $11 at Deutsche Bank
UAA Under Armour
$8.44 /

-0.475 (-5.33%)

AAP Advance Auto Parts
$126.90 /

-1.165 (-0.91%)

03/13/23 Argus
Advance Auto Parts cut to Hold at Argus on flat margins, paused buybacks
03/13/23 Argus
Advance Auto Parts downgraded to Hold from Buy at Argus
03/01/23 DA Davidson
Advance Auto Parts price target lowered to $142 from $170 at DA Davidson
03/01/23 Raymond James
Advance Auto Parts price target lowered to $180 from $200 at Raymond James
LRCX Lam Research
$473.45 /

-5.36 (-1.12%)

03/13/23 Bernstein
Lam Research downgraded to Market Perform from Outperform at Bernstein
03/09/23 Citi
Citi says HDD storage prices ticking up
03/01/23 KGI Securities
Lam Research upgraded to Outperform from Neutral at KGI Securities
01/31/23 Citi
Citi opens 'positive catalyst watch' on Lam Research
MRK Merck
$108.08 /

+0.4 (+0.37%)

03/13/23 Wells Fargo
Merck downgraded at Wells Fargo on valuation, lack of catalysts
03/13/23 Wells Fargo
Merck downgraded to Equal Weight from Overweight at Wells Fargo
03/10/23 Berenberg
Merck price target raised to $130 from $125 at Berenberg
03/09/23 Guggenheim
Merck price target raised to $123 from $116 at Guggenheim
PB Prosperity Bancshares
$59.83 /

-4.315 (-6.73%)

03/13/23 DA Davidson
Prosperity Bancshares upgraded to Buy from Neutral at DA Davidson
03/13/23 Janney Montgomery Scott
Prosperity Bancshares upgraded to Buy from Neutral at Janney Montgomery Scott
03/10/23 Morgan Stanley
SVB Financial pressures 'highly idiosyncratic,' says Morgan Stanley
PNC PNC Financial
$127.34 /

-9.82 (-7.16%)

03/13/23 Citi
PNC Financial upgraded to Buy from Neutral at Citi
02/15/23 Piper Sandler
PNC Financial price target raised to $164 from $150 at Piper Sandler
01/19/23 Baird
PNC Financial price target lowered to $205 from $210 at Baird
01/19/23 Credit Suisse
PNC Financial price target lowered to $165 from $170 at Credit Suisse
AMGN Amgen
$235.21 /

+7.33 (+3.22%)

03/13/23 Wells Fargo
Wells Fargo upgrades Amgen to Overweight, lowers target to $265
03/13/23 Wells Fargo
Amgen upgraded to Overweight from Equal Weight at Wells Fargo
02/13/23 Truist
Amgen price target lowered to $260 from $280 at Truist
02/06/23 Argus
Amgen price target lowered to $270 from $300 at Argus
LLY Eli Lilly
$327.00 /

+12.055 (+3.83%)

03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
03/06/23 Jefferies
Jefferies starts 'priced to perfection' Eli Lilly with a Hold
JPM JPMorgan
$132.32 /

-1.335 (-1.00%)

03/13/23 Wells Fargo
Wells Fargo upgrades JPMorgan on 'Goliath is Winning' theme
03/13/23 Wells Fargo
JPMorgan upgraded to Overweight from Equal Weight at Wells Fargo
02/24/23 Morgan Stanley
JPMorgan price target raised to $173 from $167 at Morgan Stanley
02/08/23 Keefe Bruyette
Keefe Bruyette downgrades 'vulnerable' Bank of America to Underperform
UA Under Armour
$7.50 /

-0.345 (-4.40%)

TSLA Tesla
$169.38 /

-4.06 (-2.34%)

SIVB SVB Financial
$105.92 /

+ (+0.00%)

SI Silvergate Capital
$2.40 /

-0.17 (-6.61%)

PNC PNC Financial
$127.34 /

-9.82 (-7.16%)

PB Prosperity Bancshares
$59.83 /

-4.315 (-6.73%)

OEC Orion Engineered
$23.87 /

-0.66 (-2.69%)

NVEI Nuvei
$38.76 /

+1.21 (+3.22%)

NKLA Nikola
$1.69 /

+0.03 (+1.81%)

MRK Merck
$108.08 /

+0.4 (+0.37%)

LRCX Lam Research
$473.45 /

-5.36 (-1.12%)

LLY Eli Lilly
$327.00 /

+12.055 (+3.83%)

JPM JPMorgan
$132.32 /

-1.335 (-1.00%)

GEHC GE HealthCare
$74.57 /

-0.44 (-0.59%)

CBT Cabot
$73.00 /

-1.31 (-1.76%)

AMGN Amgen
$235.21 /

+7.33 (+3.22%)

AAP Advance Auto Parts
$126.90 /

-1.165 (-0.91%)

  • 10
    Mar
UA Under Armour
$7.50 /

-0.345 (-4.40%)

TSLA Tesla
$169.38 /

-4.06 (-2.34%)

SIVB SVB Financial
$105.92 /

+ (+0.00%)

SI Silvergate Capital
$2.40 /

-0.17 (-6.61%)

PNC PNC Financial
$127.34 /

-9.82 (-7.16%)

NKLA Nikola
$1.69 /

+0.03 (+1.81%)

MRK Merck
$108.08 /

+0.4 (+0.37%)

LRCX Lam Research
$473.45 /

-5.36 (-1.12%)

LLY Eli Lilly
$327.00 /

+12.055 (+3.83%)

JPM JPMorgan
$132.32 /

-1.335 (-1.00%)

GEHC GE HealthCare
$74.57 /

-0.44 (-0.59%)

AMGN Amgen
$235.21 /

+7.33 (+3.22%)

UA Under Armour
$7.50 /

-0.345 (-4.40%)

TSLA Tesla
$169.38 /

-4.06 (-2.34%)

SIVB SVB Financial
$105.92 /

+ (+0.00%)

SI Silvergate Capital
$2.40 /

-0.17 (-6.61%)

PNC PNC Financial
$127.34 /

-9.82 (-7.16%)

NVEI Nuvei
$38.76 /

+1.21 (+3.22%)

NKLA Nikola
$1.69 /

+0.03 (+1.81%)

MRK Merck
$108.08 /

+0.4 (+0.37%)

LRCX Lam Research
$473.45 /

-5.36 (-1.12%)

LLY Eli Lilly
$327.00 /

+12.055 (+3.83%)

JPM JPMorgan
$132.32 /

-1.335 (-1.00%)

GEHC GE HealthCare
$74.57 /

-0.44 (-0.59%)

AMGN Amgen
$235.21 /

+7.33 (+3.22%)

AAP Advance Auto Parts
$126.90 /

-1.165 (-0.91%)

UAA Under Armour
$8.44 /

-0.475 (-5.33%)

TSLA Tesla
$169.38 /

-4.06 (-2.34%)

SIVB SVB Financial
$105.92 /

+ (+0.00%)

SI Silvergate Capital
$2.40 /

-0.17 (-6.61%)

PNC PNC Financial
$127.34 /

-9.82 (-7.16%)

NKLA Nikola
$1.69 /

+0.03 (+1.81%)

MRK Merck
$108.08 /

+0.4 (+0.37%)

LRCX Lam Research
$473.45 /

-5.36 (-1.12%)

LLY Eli Lilly
$327.00 /

+12.055 (+3.83%)

JPM JPMorgan
$132.32 /

-1.335 (-1.00%)

GEHC GE HealthCare
$74.57 /

-0.44 (-0.59%)

AMGN Amgen
$235.21 /

+7.33 (+3.22%)

AAP Advance Auto Parts
$126.90 /

-1.165 (-0.91%)

Options
Early notable gainers among liquid option names on March 13th » 09:55
03/13/23
03/13
09:55
03/13/23
09:55
ILMN

Illumina

$217.36 /

+23.24 (+11.97%)

, NEM

Newmont

$44.17 /

+2.01 (+4.77%)

, MRNA

Moderna

$142.77 /

+4.49 (+3.25%)

, LLY

Eli Lilly

$322.45 /

+7.505 (+2.38%)

, CCI

Crown Castle

$128.23 /

+1.37 (+1.08%)

Notable gainers among…

Notable gainers among liquid option names this morning include Illumina (ILMN) $222.65 +28.64, Newmont Mining (NEM) $44.23 +2.07, Moderna (MRNA) $143.27 +4.98, Eli Lilly (LLY) $326.23 +11.21, and Crown Castle (CCI) $131.31 +4.44.

ShowHide Related Items >><<
NEM Newmont
$44.17 /

+2.01 (+4.77%)

MRNA Moderna
$142.77 /

+4.49 (+3.25%)

LLY Eli Lilly
$322.45 /

+7.505 (+2.38%)

ILMN Illumina
$217.36 /

+23.24 (+11.97%)

CCI Crown Castle
$128.23 /

+1.37 (+1.08%)

ILMN Illumina
$217.36 /

+23.24 (+11.97%)

03/13/23 Piper Sandler
Piper agrees with Icahn, says Illumina base business undervalued
02/14/23 UBS
Illumina price target lowered to $240 from $255 at UBS
02/08/23 Stifel
Illumina price target lowered to $235 from $285 at Stifel
02/08/23 RBC Capital
Illumina price target raised to $303 from $284 at RBC Capital
NEM Newmont
$44.17 /

+2.01 (+4.77%)

02/24/23 TD Securities
Newmont upgraded to Buy at TD Securities following 20% correction
02/24/23 TD Securities
Newmont upgraded to Buy from Hold at TD Securities
02/16/23 Jefferies
Newcrest Mining downgraded to Hold from Buy at Jefferies
02/14/23 UBS
UBS downgrades Newmont ahead of expected dividend cut
MRNA Moderna
$142.77 /

+4.49 (+3.25%)

03/13/23 TD Cowen
Moderna upgraded to Outperform from Market Perform at TD Cowen
03/07/23 TD Cowen
Moderna sees several disease growth opportunities, says TD Cowen
03/01/23 RBC Capital
Moderna initiated with an Outperform at RBC Capital
02/28/23 Deutsche Bank
Moderna price target lowered to $200 from $225 at Deutsche Bank
LLY Eli Lilly
$322.45 /

+7.505 (+2.38%)

03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
03/06/23 Jefferies
Jefferies starts 'priced to perfection' Eli Lilly with a Hold
CCI Crown Castle
$128.23 /

+1.37 (+1.08%)

01/31/23 RBC Capital
Crown Castle price target raised to $162 from $150 at RBC Capital
01/27/23 TD Cowen
Crown Castle price target raised to $152 from $149 at Cowen
01/23/23 KeyBanc
Crown Castle downgraded to Sector Weight from Overweight at KeyBanc
01/13/23 Truist
Crown Castle price target lowered to $175 from $230 at Truist
NEM Newmont
$44.17 /

+2.01 (+4.77%)

MRNA Moderna
$142.77 /

+4.49 (+3.25%)

LLY Eli Lilly
$322.45 /

+7.505 (+2.38%)

ILMN Illumina
$217.36 /

+23.24 (+11.97%)

CCI Crown Castle
$128.23 /

+1.37 (+1.08%)

NEM Newmont
$44.17 /

+2.01 (+4.77%)

MRNA Moderna
$142.77 /

+4.49 (+3.25%)

LLY Eli Lilly
$322.45 /

+7.505 (+2.38%)

ILMN Illumina
$217.36 /

+23.24 (+11.97%)

CCI Crown Castle
$128.23 /

+1.37 (+1.08%)

NEM Newmont
$44.17 /

+2.01 (+4.77%)

MRNA Moderna
$142.77 /

+4.49 (+3.25%)

LLY Eli Lilly
$322.45 /

+7.505 (+2.38%)

ILMN Illumina
$217.36 /

+23.24 (+11.97%)

NEM Newmont
$44.17 /

+2.01 (+4.77%)

MRNA Moderna
$142.77 /

+4.49 (+3.25%)

LLY Eli Lilly
$322.45 /

+7.505 (+2.38%)

ILMN Illumina
$217.36 /

+23.24 (+11.97%)

CCI Crown Castle
$128.23 /

+1.37 (+1.08%)

Upgrade
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo » 08:18
03/13/23
03/13
08:18
03/13/23
08:18
LLY

Eli Lilly

$314.92 /

-1.99 (-0.63%)

Wells Fargo upgraded Eli…

Wells Fargo upgraded Eli Lilly to Overweight from Equal Weight with a price target of $375, up from $360. The recent weakness in the shares creates a buying opportunity as Lilly's fundamentals remain the same, the analyst tells investors in a research note. As current share levels, the risk/reward into the donanemab Alzheimer's trial "may be skewed to the upside," contends the firm. Wells says the stock is down 18% from its peak without any fundamental change. This is a good opportunity to own the highest growth stock in the large pharma sector, it writes.

ShowHide Related Items >><<
LLY Eli Lilly
$314.92 /

-1.99 (-0.63%)

LLY Eli Lilly
$314.92 /

-1.99 (-0.63%)

03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
03/06/23 Jefferies
Jefferies starts 'priced to perfection' Eli Lilly with a Hold
03/06/23 Jefferies
Eli Lilly initiated with a Hold at Jefferies
LLY Eli Lilly
$314.92 /

-1.99 (-0.63%)

LLY Eli Lilly
$314.92 /

-1.99 (-0.63%)

LLY Eli Lilly
$314.92 /

-1.99 (-0.63%)

LLY Eli Lilly
$314.92 /

-1.99 (-0.63%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.